Gilead 3Q Revenues: $7.5 billion (+7%) 3Q Earnings: $1.25 billion (-42%) YTD Revenues: $21.2 billion (+6%) YTD Loss: $1.3 billion (earnings were $4.4 billion YTD23) Comments: Growth in the quarter primarily due to higher sales in HIV as well as in Veklury (remdesivir), Oncology and Liver Disease. Biktarvy sales were up 13% to $3.5 billion in the quarter. Descovy sales were up 15% to $586 million. The Liver Disease portfolio sales increased 4% to $733 million in the quarter primarily driven ...